CSIMarket


Arrowhead Pharmaceuticals Inc   (ARWR)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare


 

Arrowhead Pharmaceuticals Inc

ARWR's Financial Statements and Analysis



Arrowhead Pharmaceuticals Inc increased IV. Quarter net loss per share of $-0.81 compare to net loss per share of $-0.61 recorded in the same quarter a year ago a decrease compare to $-0.68 realized in previous quarter.


IV. Quarter
Earnings Per Share Revenues
$ -0.81 $  32 Mill
$-0.20     $-7M     -17.52 %



Arrowhead Pharmaceuticals Inc 's Revenue fell by -17.52 % in IV. Quarter (Sep 30 2022) year on year, to $32 million and declined by -2.58 % sequentially.


Arrowhead Pharmaceuticals Inc is Expected to report next financial results on May 09, 2023.

More on ARWR's Income Statement



Arrowhead Pharmaceuticals Inc 's in IV. Quarter recorded net loss of $-85.942 million, an increase from net loss of $-63.374 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on ARWR's Growth

In IV. Quarter company's net cash and cash equivalents decreased by $-31 million, capital expenditures fell by 298.96%, to $-33 millions compare to same quarter a year ago and fell by 243.03% from III. Quarter (Jun 30 2022).

More on ARWR's Cash flow Statement


Arrowhead Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Arrowhead Pharmaceuticals Inc payed $ -1.29 cash per share, on a free-cash flow basis .